Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Genor Bio Closes $160 Million B Round to Develop Ten Biologic Clinical Candidates

publication date: Jun 1, 2020

Genor Biopharma, a Shanghai company with ten biologic candidates in clinical trials, completed a $160 million Series B financing led by Beijing's Hillhouse Capital Group. The company's PD-1 molecule is currently in four pivotal Phase II trials. Its other clinical stage assets are mAbs and recombinant fusion proteins, a combination of novel drugs and biosimilars that target indications in cancer and autoimmune diseases. In late 2019, Genor was rumored to be planning a $200 million IPO on the Hong Kong Exchange, but that offering has not been officially announced. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here